H3 Biomedicine Inc.

56 articles about H3 Biomedicine Inc.

• 

  Genetown's Growing Pains: Eisai Shutters H3 Bio, Biogen Job Cuts have Begun

  7/19/2022

  The Bay State, home to the busy bio-hub Genetown, is experiencing some growing pains. Companies like Biogen and Eisai (H3 Biomedicine) are reducing their headcount.

• H3 Biomedicine Welcomes Dr. Richard Woodman to its Board of Directors

  1/10/2022

  H3 Biomedicine Inc. today announced the addition of Richard Woodman, M.D. to its Board of Directors (“Board”).

• H3 Biomedicine Presents Investigational Data Update on H3B-6545 for Treatment of Locally Advanced or Metastatic Estrogen Receptor- positive, HER2-negative Breast Cancer at San Antonio Breast Cancer Symposium

  12/8/2021

  H3 Biomedicine Inc. today announced the presentation of two posters at the 2021 San Antonio Breast Cancer Symposium (SABCS) being held in a hybrid format on December 7- 10, 2021.

• H3 Biomedicine Presents Update on Intratumoral E7766 Clinical Program for Advanced Solid Tumors or Lymphomas at AACR-NCI-EORTC Conference

  10/8/2021

  H3 Biomedicine Inc. today announced it will be providing an update on its intratumoral E7766 clinical program for advanced solid tumors or lymphomas in a poster presentation at the 2021 American Association for Cancer Research

• H3 Biomedicine Announces Presentation of Four Abstracts at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

  5/20/2021

  H3 Biomedicine Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the presentation of four posters providing updated investigational data on its H3B-6545 clinical program for breast cancer and its H3B-6527 clinical program for hepatocellular carcinoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4–8,

• H3 Biomedicine, Inc. Presents Data Update on H3B-6545 for Treatment of Locally Advanced or Metastatic Estrogen Receptor-positive, HER2-negative Breast Cancer at San Antonio Breast Cancer Symposium

  12/8/2020

  H3 Biomedicine, Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the presentation of three posters at the 2020 San Antonio Breast Cancer Symposium (SABCS). The presentations include interim data from H3’s ongoing Phase 1/2 clinical development program, H3B-6545, a potential first-in-class, orally available Selective ERα Covalent Antagonist (SERCA), in

• 

  BioSpace Movers & Shakers, Feb. 21

  2/21/2020

  Biopharma and life sciences companies strengthen their leadership teams and board with this week's Movers & Shakers.

• H3 Biomedicine Announces Appointment of Chief Medical Officer, Antonio Gualberto

  2/19/2020

  Feb. 19, 2020 13:00 UTC Industry veteran to helm newly created position as H3 advances oncology pipeline CAMBRIDGE, Mass.--( BUSINESS WIRE )-- H3 Biomedicine, Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the appointment of Antonio Gualberto, MD, PhD, to the position of Chief Medical Officer (CMO). Dr. Gualberto will oversee global clinical research & development for the H3 pipeline of clinical sta

• H3 Biomedicine to Present Data from Two Ongoing Precision Medicine Clinical Programs at 2019 ASCO Annual Meeting

  5/16/2019

  H3 Biomedicine Inc., a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., announced it will present four posters during the 2019 American Society of Clinical Oncology Annual Meeting, which will be held May 31 – June 4, 2019 in Chicago.

• H3 Biomedicine Announces Multiple Presentations at Upcoming AACR Annual Meeting

  3/25/2019

  Presentations highlight company’s expertise seamlessly integrating human biology, data science and modern chemistry to advance a pipeline of investigational breakthrough precision oncology medicines

• Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3’s RNA Splicing Platform

  12/17/2018

  Bristol-Myers Squibb Company (NYSE: BMY), Eisai Co., Ltd. and its U.S.-based precision medicine research & development subsidiary H3 Biomedicine Inc. (Massachusetts, “H3”) today announced a multi-year research collaboration focused on evaluating whether novel therapeutics leveraging H3’s RNA splicing platform can provide a more powerful response against cancer.

• Distributed Bio Inc. Announces Collaboration with H3 Biomedicine

  10/30/2018

  Distributed Bio, the global leader in computational optimization of fully human monoclonal antibody libraries, today announced a discovery collaboration with H3 Biomedicine Inc. designed to help accelerate the discovery of novel cancer therapeutics.

• Cancer Discovery Features H3 Biomedicine Paper Highlighting Effects of Selective Estrogen Receptor Covalent Antagonists (SERCAs) in ERα Wild-Type and Mutant Breast Cancer Models

  7/10/2018

  Next-generation endocrine therapy exhibits differentiated mechanism of action versus standard-of-care therapies and potently inhibits the ERα pathway

• Lihua Yu, Ph.D., Appointed President & Chief Data Sciences Officer, H3 Biomedicine

  6/11/2018

  Eisai Inc. announced the appointment of Lihua Yu, Ph.D., to President & Chief Data Sciences Officer, H3 Biomedicine, the cancer genomics based drug discovery company of Eisai.

• 

  AACR Meeting Brief: H3 Biomedicine, Checkmate, Deciphera and More

  4/17/2018

  The following is a roundup of presentations and findings from multiple companies participating in the 2018 American Association for Cancer Research (AACR) in Chicago.

• H3 Biomedicine Reports Discovery of Recurrent RNA Splicing Factor Mutations in Non-Hodgkin’s Lymphoma and Multiple Myeloma

  4/17/2018

  -- Expands potential addressable patient population for H3 Biomedicine’s lead splicing modulator H3B-8800, currently in Phase 1 study for other hematologic malignancies -- -- Underscores promise of H3 Biomedicine’s product engine to identify previously unknown cancer drivers to inform discovery and development of next-generation targeted therapies --

• H3 Biomedicine Publishes Comprehensive Genomic Landscape Analysis in Cell Reports Revealing Breadth, Frequency and Potential Disease-Driving Significance of Somatic Mutations in RNA Splicing Factor Genes in Multiple Types of Cancer

  4/3/2018

  Novel findings underscore promise of H3 Biomedicine’s first-in-class splicing factor modulator H3B-8800 currently in Phase 1 clinical trial for patients with hematologic cancers and splicing factor mutations

• H3 Biomedicine to Present at the BioCentury Annual Future Leaders in the Biotech Industry Conference

  3/19/2018

  H3 Biomedicine Inc. announced that management will present an overview of the company at the BioCentury 25th Annual Future Leaders in the Biotech Industry Conference on Friday, March 23, 2018, at 10:15 a.m. EST at the Millennium Broadway Hotel & Conference Center in New York.

• H3 Biomedicine to Present at 2018 BIO CEO & Investor Conference

  2/5/2018

  H3 Biomedicine announced that company management will present an overview of the company at the 2018 BIO CEO & Investor Conference on Monday, February 12, 2018, at 9:45 a.m. EST at the New York Marriott Marquis in New York.

• H3 Biomedicine’s Preclinical Data Highlighting Novel Discovery Research in Hepatocellular Carcinoma Published in December Issue of Cancer Research

  12/15/2017

  The data were recently presented at the International Liver Cancer Association annual meeting held in Seoul, Republic of Korea.